40 compounds · from $17.99
Slimmaxxing — GLP-1, GIP & Triple-Agonist Compounds
Slimmaxxing is the shelf people arrive here for, and it splits cleanly in two. The incretin half is the familiar one: Semaglutide, the GLP-1 monoagonist behind Ozempic and Wegovy; Tirzepatide, which adds GIP receptor activity; and Retatrutide, the triagonist that layers glucagon receptor activation on top of both. Cagrilintide sits slightly apart as an amylin analogue, engaging a satiety pathway that runs parallel to GLP-1 rather than overlapping it, which is why the two get co-formulated. The non-incretin half is where the harder-to-find compounds live — 5-Amino-1MQ as an oral NNMT inhibitor, BAM-15 as a mitochondrial uncoupler, SLU-PP-332 as an ERR agonist, plus AOD9604, Adipotide and Tesofensine. Everything below is priced from the single supplier we verify against, with an HPLC certificate on every vial.
Tirzepatide 15mg
$134.99
5-Amino-1MQ 50mg
$71.99
5-Amino-1MQ 50mg x60 Capsules
$107.99
5-Amino-1MQ 5mg
$17.99
AOD9604 10mg
$107.99
AOD9604 2mg
$35.99
AOD9604 5mg
$62.99
Adipotide (FTPP) 10mg
$134.99
Adipotide (FTPP) 5mg
$80.99
BAM-15 30mg/mL 30mL
$80.99
BAM-15 50mg/mL 30mL
$116.99
Cagri-Reta 10mg
$170.99
Cagri-Reta 5mg
$116.99
Cagri-Sema Blend 10mg
$161.99
Cagrilintide 10mg
$152.99
Cagrilintide 5mg
$89.99
L-Carnitine 400mg/mL
$35.99
L-Carnitine 5-Pack 600mg
$80.99
L-Carnitine 600mg/mL
$44.99
Mazdutide 6mg
$116.99
Reta-Cagri 5mg/5mg
$134.99
Retatrutide 10mg
$134.99
Retatrutide 15mg
$179.99
Retatrutide 20mg
$224.99
Retatrutide 30mg
$296.99
SLU-PP-332 100mg x120 Capsules
$143.99
SLU-PP-332 100mg x30 Capsules
$53.99
SLU-PP-332 1mg x30 Capsules
$35.99
SLU-PP-332 1mg/mL 30mL
$71.99
SLU-PP-332 5mg/mL 30mL
$89.99
Semaglutide 12mg
$116.99
Semaglutide 20mg
$170.99
Semaglutide 30mg
$224.99
Semaglutide 3mg
$44.99
Semaglutide 6mg
$71.99
Survodutide 10mg
$143.99
Tesofensine 500mcg x30 Capsules
$89.99
Tesofensine 500mcg x30 Tablets
$89.99
Tirzepatide 30mg
$224.99
Tirzepatide 60mg
$359.99
How the Three Incretin Tiers Differ
The gap between the three headline compounds is receptor count, and the trial data tracks it almost linearly. Semaglutide hits GLP-1 alone and recorded −14.9% mean body weight over 68 weeks in STEP 1. Tirzepatide adds GIP receptor agonism, which improves insulin-stimulated glucose uptake in adipose tissue and appears to blunt some of the GI burden — SURMOUNT-1 put it at −20.9% over 72 weeks. Retatrutide adds glucagon receptor activation on top of both, and that third receptor is an energy-expenditure mechanism rather than an appetite one: hepatic beta-oxidation and brown adipose thermogenesis. Its Phase 2 result of −28.7% at 48 weeks had not plateaued when the trial ended.
Why Escalation Schedules Are Not Optional
Every compound on this shelf that touches the GLP-1 receptor slows gastric emptying, and that is the direct cause of the nausea and motility complaints that show up in the first weeks. The standard answer is a four-week step schedule from the minimum effective dose, which is what the STEP, SURMOUNT and Retatrutide Phase 2 protocols all used. Skipping steps does not change where you end up, only how rough the trip is — adverse event rates climb sharply without the adaptation window. This is also why BPC-157 is the single most common add-on for anyone running a compound from this shelf.
The Non-Incretin Outliers
Not everything here works through appetite. 5-Amino-1MQ inhibits nicotinamide N-methyltransferase to raise intracellular NAD+ and reduce triglyceride accumulation in adipocytes, and it ships as an oral capsule rather than an injectable. BAM-15 is a mitochondrial protonophore — it uncouples oxidative phosphorylation so energy dissipates as heat instead of being stored. SLU-PP-332 activates estrogen-related receptors to mimic aspects of the exercise response. These are earlier-stage compounds with thinner evidence than the incretins, and they belong in a protocol as adjuncts, not substitutes.